The Wet Age-Related Macular Degeneration market continues to demonstrate robust expansion across major markets worldwide. In 2023, the market size of Wet Age-Related Macular Degeneration (Wet AMD) was highest in the US among the 7MM, accounting for approximately USD 2,599 million, which is further expected to rise significantly by 2036. Meanwhile, the market size of Wet AMD in Japan stood at USD 1,163 million in 2023, reflecting strong regional demand and therapeutic adoption across Asia-Pacific.
According to DelveInsight estimates, in 2025, the total prevalent cases of AMD were nearly 72 million in the 7MM, underscoring the enormous patient burden that continues to drive investment and innovation in this therapeutic space.
Various therapies are employed to treat Wet AMD, and currently approved options include EYLEA (aflibercept), LUCENTIS (ranibizumab), BEOVU (brolucizumab), AVASTIN (bevacizumab), and others. Among these, EYLEA held the highest market share in 2023, accounting for approximately USD 4,276 million in the 7MM, according to DelveInsight analysis. The Wet Age-Related Macular Degeneration market research indicates that the market is driven by an aging global population, a pipeline of innovative therapies, and increased screening programs, while high treatment costs, limited patient access, and treatment burden remain key barriers. Reimbursement landscapes vary across geographies, with a growing emphasis on value-based care models. Key unmet needs include longer-acting therapies, improved treatment efficacy, and better early detection methods.
Access in-depth Wet Age-Related Macular Degeneration market research and gain a competitive edge in this high-growth therapeutic area.
Wet Age-Related Macular Degeneration (Wet AMD) Overview
Wet Age-Related Macular Degeneration (Wet AMD) is a chronic eye disorder resulting from the abnormal growth of blood vessels beneath the macula – a small area of the retina responsible for central vision. These newly formed vessels leak blood and fluid, causing rapid and severe vision loss. The primary risk factors include advanced age, genetic predisposition, and lifestyle factors such as smoking. Wet AMD is typically more severe than its counterpart, dry AMD, and can lead to permanent central vision impairment if not diagnosed and treated promptly. Its progressive nature, combined with the lack of curative options, makes it one of the most consequential ophthalmic conditions in the aging population.
Wet Age-Related Macular Degeneration (Wet AMD) Diagnosis
Diagnosing Wet AMD involves a multi-step clinical evaluation process. An initial comprehensive eye examination with dilated fundus photography is conducted to visualize the retina and macula. Optical coherence tomography (OCT) plays an essential role in identifying fluid or blood accumulation under the retina, which is indicative of active disease. Fluorescein angiography may also be employed to detect leaking blood vessels in the macula.
Symptoms typically prompting diagnostic workup include blurred vision, dark spots, or distorted lines in the central visual field. Early detection remains critical, as prompt therapeutic intervention can meaningfully slow disease progression and help preserve functional vision. Patients with confirmed Wet AMD require ongoing monitoring, regular imaging follow-ups, and sustained medical management throughout the course of their disease.
Wet Age-Related Macular Degeneration (Wet AMD) Treatment
Treatment for Wet AMD primarily focuses on halting disease progression and preserving vision. The current standard of care revolves around anti-VEGF (vascular endothelial growth factor) agents, including Ranibizumab (Lucentis), Aflibercept (Eylea), and Brolucizumab (Beovu). These therapies are administered via intravitreal injections and work by reducing pathological blood vessel growth and fluid leakage in the retina. Some patients may also benefit from photodynamic therapy (PDT), which uses light-activated drugs to selectively destroy abnormal blood vessels while minimizing damage to surrounding tissue.
The field is rapidly evolving, with advances in gene therapy and implantable drug delivery devices under active investigation. These next-generation solutions aim to provide more durable treatment outcomes, reduce injection frequency, and ultimately improve quality of life for patients living with Wet AMD. The Wet Age-Related Macular Degeneration market insight reinforces that treatment innovation remains at the center of market dynamics heading into the next decade.
Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology
The Wet AMD epidemiology landscape provides historical and forecasted data segmented by total prevalent cases of AMD, diagnosed prevalent cases, type-specific diagnosed prevalent cases, and total age-specific cases of Wet AMD across the 7MM – covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2022 to 2036.
- According to DelveInsight estimates, the total prevalent cases of AMD in the 7MM were nearly 72 million in 2025.
- The US accounted for the second highest number of diagnosed prevalent cases of Wet AMD, representing approximately 26% of total diagnosed prevalent cases across the 7MM.
- In the US, total age-specific Wet AMD cases in 2025 were approximately 99,800 in the ≤64 years group, 425,500 in the 65–84 years group, and 493,500 in the 85+ years group.
- Among EU4 countries and the UK, France recorded the highest number of diagnosed prevalent Wet AMD cases, while the UK accounted for the least number of cases in 2025.
These epidemiological insights form the foundation of the patient-based market model and reinforce the substantial and growing disease burden that pharmaceutical companies and healthcare systems must address in the years ahead.
Wet Age-Related Macular Degeneration (Wet AMD) Recent Developments
The Wet AMD pipeline and regulatory landscape have witnessed significant activity in recent months, reflecting the intensity of innovation in this space:
- In March 2026, Outlook Therapeutics provided an update following its recent Type A meeting with the US FDA to discuss a Complete Response Letter (CRL) for the Biologics License Application (BLA) for bevacizumab (LYTENAVA) for the treatment of Wet AMD.
- In December 2025, Outlook Therapeutics announced that the US FDA issued a CRL declining to approve bevacizumab (LYTENAVA) for the treatment of Wet AMD.
- In October 2025, Regenxbio announced the completion of Phase II pivotal trials (ATMOSPHERE and ASCENT) evaluating surabgene lomparvovec (RGX-314) for Wet AMD, with topline data expected in 2026.
- In September 2025, Roche presented new data from the AVONELLE-X and SALWEEN studies of VABYSMO at the 25th Euretina Congress, highlighting sustained efficacy, safety, and durability over four years in patients with Wet AMD.
- In September 2025, Adverum Biotechnologies announced that screening for ARTEMIS – its first pivotal Phase III trial evaluating Ixo-vec in Wet AMD – was expected to be completed by September 30, with a data readout anticipated in Q1 2027.
Wet Age-Related Macular Degeneration Marketed Drugs
- BEOVU (Brolucizumab) – Novartis
BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment for Wet AMD. It works by inhibiting vascular endothelial growth factor, thereby reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU is designed to offer extended dosing intervals, supporting dosing schedules of up to every 12 weeks, which may reduce the overall treatment burden for patients and caregivers alike.
- EYLEA (Aflibercept) – Regeneron Pharmaceuticals
EYLEA (aflibercept), developed by Regeneron Pharmaceuticals, is used to treat Wet AMD, diabetic eye disease, and other retinal conditions. The drug functions as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation in the retina. The standard dosing regimen involves 2 mg administered every 4 weeks for the first three months, followed by injections every 8 weeks. EYLEA received FDA approval in November 2011 for Wet AMD, followed by European Commission approval in November 2012 and Japan’s MHLW approval in September 2012. Regeneron is currently evaluating less frequent dosing regimens and higher dose formulations in ongoing Phase III trials.
- VABYSMO (Faricimab) – Roche/Genentech, Inc.
VABYSMO (faricimab) is the first bispecific antibody engineered for the eye, targeting and inhibiting two key signalling pathways linked to vision-threatening retinal conditions. It neutralizes both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – two proteins that contribute to vision loss by destabilizing blood vessels, promoting the formation of new leaky vessels, and increasing retinal inflammation. By blocking both pathways simultaneously, VABYSMO is designed to stabilize blood vessels more comprehensively than single-target agents. VABYSMO is now approved in the European Union and more than nine countries worldwide, including the US, Japan, and the UK, for patients living with Wet AMD and diabetic macular edema.
Wet Age-Related Macular Degeneration Emerging Drugs
- Ixoberogene Soroparvovec (Ixo-vec) – Adverum Biotechnologies
Ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022) is Adverum’s clinical-stage gene therapy candidate for the treatment of Wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. The therapy is designed to provide a durable, safe, and cost-effective in-office treatment option for patients, families, retina specialists, and health systems globally. The FDA has granted both Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for Ixo-vec. It has also received PRIME designation from the EMA and the Innovation Passport from the UK’s Medicines and Healthcare Products Regulatory Agency. Ixo-vec is currently being evaluated in a Phase III pivotal trial.
- Surabgene Lomparvovec (RGX-314) – Regenxbio/AbbVie
RGX-314 is being developed as a novel, potentially one-time subretinal treatment utilizing the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize VEGF activity, modifying the pathway responsible for leaky blood vessel formation and retinal fluid accumulation. RGX-314 is currently being evaluated in patients with Wet AMD in Phase III and Phase II/III clinical trials, and the company anticipates submitting global regulatory applications in the first half of 2026.
- OGX-110 – Ocugenix
OGX-110 is a novel small molecule therapy in development for Wet AMD, engineered to target both abnormal blood vessels and retinal fibrosis – two key drivers of disease progression and irreversible blindness. OGX-110 selectively activates the CXCR3 pathway, a natural wound-healing mechanism in the retina, which noncompetitively overrides pro-angiogenic and pro-fibrotic signals, including VEGF, leading to regression of pathological neovascularization and fibrotic tissue rather than simply controlling edema. The drug is currently in an active Phase I clinical trial for Wet AMD.
Discover the full scope of the Wet Age-Related Macular Degeneration market landscape, epidemiology, and pipeline insights today.
Leading Wet AMD Companies Developing Therapies
The Wet Age-Related Macular Degeneration market trends are being shaped by a diverse and active competitive landscape. Key companies developing therapies across the Wet AMD space include:
- Regeneron Pharmaceuticals
- Novartis
- Pfizer
- Roche
- Chengdu Kanghong Biotech
- Kodiak Sciences Inc.
- Opthea Limited
- Alkahest Inc.
- Graybug Vision
- REGENXBIO
- PanOptica, Inc.
- Clearside Biomedical
- Hemera Biosciences
- Ribomic USA Inc.
- and others.
These organizations are collectively driving forward a pipeline of next-generation anti-VEGF agents, gene therapies, bispecific antibodies, and sustained-release platforms that could meaningfully reshape the treatment paradigm for Wet AMD patients worldwide over the coming decade.
Conclusion
The global Wet Age-Related Macular Degeneration (Wet AMD) market is poised for substantial growth through 2036, driven by a rising aging population, increasing disease prevalence, and continuous therapeutic innovation. Advances in anti-VEGF therapies, gene therapies, and long-acting treatment approaches are reshaping the treatment landscape and improving patient outcomes. Despite challenges such as high treatment costs and frequent injection burdens, ongoing research and regulatory progress continue to create new opportunities in the market. With strong participation from leading pharmaceutical companies and a robust clinical pipeline, the Wet AMD market is expected to witness sustained expansion, enhanced treatment accessibility, and significant advancements in vision preservation strategies worldwide.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
